<DOC>
	<DOCNO>NCT00640263</DOCNO>
	<brief_summary>The ANRS 12174 study clinical trial compare efficacy safety prolong infant peri-exposure prophylaxis ( PEP ) Lopinavir/Ritonavir ( LPV/r ) versus Lamivudine prevent HIV-1 transmission breast milk child bear HIV-1-infected mother eligible HAART benefit perinatal antiretroviral ( ART ) regimens . The study recruit 1500 mother-infant pair 4 African country . Study design : PROMISE PEP multinational , randomise double-blind control clinical trial . Intervention : Infants randomise receive LPV/r 3TC twice daily day seven ( ± 2 day ) birth 4 week cessation breastfeeding ( BF ) . We recommend exclusive BF ( EBF ) till include 26th week life follow relatively rapid ( maximum 8 week ) cessation period . The maximum duration PEP thereby 38 week . Primary objective : To compare efficacy infant LPV/r ( 40/10mg twice daily 2-4kg 80/20mg twice daily &gt; 4kg ) vs. Lamivudine 7,5mg twice daily 2-4kg , 25mg twice daily 4-8kg 50mg twice daily &gt; 8kg ) day 7 4 week cessation BF ( maximum duration prophylaxis : 50 week maximum duration breastfeed 46 week ) prevent postnatal HIV-1 acquisition 7 day 50 week age . Secondary objective : - To assess safety long-term infant prophylaxis LPV/r versus Lamivudine ( include resistance , adverse event growth ) 50 week . - HIV-1-free survival 50 week - To build clinical trial capacity four study site . Main endpoint : Acquisition HIV-1 ( assess HIV-1 DNA PCR ) day 7 50 week age Study population : HIV-uninfected infant day 7 ( ± 2 day ) bear HIV-1 infected mother eligible HAART choose breastfeed infant benefit national prevention mother child transmission ( PMTCT ) program pregnancy delivery . The study recruit 1500 mother-infant pair Burkina Faso , South Africa , Uganda Zambia . Study duration : Infants follow 50 week total study duration five year . Expected outcome : This study inform relative advantage ( efficacy ) drawbacks two intervention support HIV-1-infected woman eligible HAART safely breastfeed baby . If find safe efficacious , regimen would avoid exist contradiction optimal infant feed prevention MTCT breast milk . Clinical trial capacity development improve future quality trial conduct country .</brief_summary>
	<brief_title>Comparison Efficacy Safety Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine Prevent HIV-1 Transmission Breastfeeding</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>A baby include she/he : singleton breastfed day 7 her/his mother her/his mother intend continue breastfeed least 6 month postpartum blood sample negative HIV1 DNA PCR test result day 7 ( +/ 2 day ) receive ART part PMTCT mother : reach local legal age participate medical research study show HIV1 infect ( without HIV2 infection ) eligible HAART take HAART receive perinatal antiretroviral prophylaxis pregnancy delivery , CD4 count threshold HAART initiation pregnant woman accord national recommendation site ( minimum 230 cells/µL ) , resides within study area intend move area next year give assent infant participate give consent participate S/he present clinical symptom and/or biological abnormality equal great grade II ANRS classification adverse event day enrolment S/he present serious congenital malformation ( ) Her/his birth weight low 2.0 kg Her/his antiretroviral prophylaxis extend beyond day 7 The mother participate trial previous pregnancy S/he her/his mother participate another clinical trial day enrolment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Days</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Breastfeeding</keyword>
	<keyword>Prevention</keyword>
	<keyword>lamivudine</keyword>
	<keyword>lopinavir/ritonavir</keyword>
</DOC>